Cetera Investment Advisers
WINT

Cetera Investment Advisers’s Windtree Therapeutics WINT Stock Holding History

Cetera Investment Advisers’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$5.07K – 2254
2022
Q4 		$5.07K Buy
+1
New +$8.89K ﹤0.01% 2088
2022
Q3 		– Hold
0
– – – 1674

Other funds holding WINT

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Cetera Investment Advisers's WINT Position: Q1 2023 in Review

Cetera Investment Advisers sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 1 share — an estimated $5.07K sold.

Cetera Investment Advisers first reported a position in WINT in Q4 2022 and held it in 1 quarter. The position peaked at $5.07K in Q4 2022. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

  • Cetera Investment Advisers reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cetera Investment Advisers sold 1 Windtree Therapeutics share in Q1 2023, an estimated $5.07K.
  • Cetera Investment Advisers first reported a position in Windtree Therapeutics in Q4 2022 and held it in 1 quarter.
  • Cetera Investment Advisers's Windtree Therapeutics position peaked at $5.07K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Cetera Investment Advisers's 13F filing for Q1 2023, filed 15 May 2023.